Rss Top Picks FeedRss Daily Feed| Click Here to receive daily reports of the TOP PICKS OR your personal stock choices | STOCKCHASEWhat the experts are saying! |
| There are 3 registered members and 45 guests viewing the site. | Follow us on Twitter | Rss Top Picks Feed | Rss Daily Feed |
|
| Comment | 2.580 | Peter Hodson | (Market Call Minute.)Reversing of bad cholesterol in clinical studies. A little early for him but has potential. Speculative. | 2009-11-16 | |
| Comment | 2.790 | Peter Hodson | Only process that can reverse a cholesterol situation. A lot of big pharmas are looking at the name. Looks pretty attractive at this level. This is at phase 2 and he prefers buying after phase 3. | 2009-08-06 | |
| Comment | 15.420 | Hugh Cleland, CFA | Have some compounds that are expected to boost HDL levels significantly. He usually has trouble with pure biotechs, which this one is. They consume vast amounts of cash. Prefers Neptune (NTB-X). | 2007-12-27 | |
| DON'T BUY | 16.900 | Hugh Cleland, CFA | Strong management. Have an interesting approach to HDL. Currently pre-clinical, so doesn't know if it works in humans or is safe. | 2007-03-26 | |
| DON'T BUY | 19.110 | Hugh Cleland, CFA | Treatment of Cardiovascular diseases. They’re on to a new way of looking at HDL treatment. Still pre-clinical. Prefers biotech that is at least in phase 2 trials. Too expensive. | 2007-01-24 |
